Use of Risk Evaluation and Mitigation Strategies by the US Food and Drug Administration, 2008-2019

JAMA. 2020 Jul 21;324(3):299-301. doi: 10.1001/jama.2020.6611.

Authors

Jenny S Guadamuz¹, Dima M Qato¹, G Caleb Alexander²

Affiliations

¹ Department of Pharmacy Systems, Outcomes and Policy, University of Illinois at Chicago College of Pharmacy.
² Center for Drug Safety and Effectiveness, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.

PMID: 32692379
DOI: 10.1001/jama.2020.6611

No abstract available

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Certification / legislation & jurisprudence
Drug Industry / legislation & jurisprudence
Drug Labeling / legislation & jurisprudence
Drug-Related Side Effects and Adverse Reactions / prevention & control*
Program Development / statistics & numerical data
Program Evaluation
Registries
Risk Evaluation and Mitigation / legislation & jurisprudence*
Time Factors
United States
United States Food and Drug Administration / legislation & jurisprudence*